

Global X Genomics & Biotechnology ETF

Ticker: GNOM

Principal Listing Exchange: Nasdaq

Annual Shareholder Report: November 30, 2024

This annual shareholder report contains important information about the Global X Genomics & Biotechnology ETF (the "Fund") for the period from December 1, 2023 to November 30, 2024. You can find additional information about the Fund at <https://www.globalxetfs.com/funds/gnom/>. You can also request this information by contacting us at 1-888-493-8631.

What were the Fund costs for the last year?

(based on a hypothetical \$10,000 investment)

Fund Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
Global X Genomics & Biotechnology ETF	\$51	0.50%

How did the Fund perform in the last year?

The Fund seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("Secondary Index"). The Fund is passively managed and the investment adviser does not attempt to take defensive positions in declining markets. The Fund generally seeks to fully replicate the Secondary Index.

The Secondary Index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the Secondary Index. These companies include those involved in the following business activities: (i) gene editing, (ii) genomic sequencing, (iii) development and testing of genetic medicine/therapies, and/or (iv) computational genomics and genetic diagnostics.

For the 12-month period ended November 29, 2024 (the "reporting period"), the Fund increased 4.03%, while the Secondary Index increased 4.76%. The Fund had a net asset value of \$10.41 per share on November 30, 2023 and ended the reporting period with a net asset value of \$10.83 per share on November 29, 2024.

During the reporting period, the highest returns came from Avidity Biosciences Inc and Poseida Therapeutics, Inc., which returned 450.96% and 248.69%, respectively. The worst performers were bluebird bio, Inc. and Editas Medicine, Inc., which returned -89.38% and -78.73%, respectively.


During the reporting period, by country, the Fund had the highest exposure to the United States at 88.1%, Switzerland at 4.4%, and Germany at 4.2%.

During the reporting period the Fund recorded positive performance. The Biotechnology sector experienced growth driven by advancements in gene editing technologies, which boosted the valuations of companies developing innovative therapies. Additionally, the FDA approval of several groundbreaking treatments from companies in the Fund's portfolio provided a tailwind. Robust funding for biomedical research, particularly in areas such as oncology and rare diseases, further supported the sector. The growing demand for personalized medicine solutions and the rising prevalence of chronic diseases globally created favorable market conditions for the Fund's holdings.

How did the Fund perform since inception?

Total Return Based on \$10,000 Investment

- Global X Genomics & Biotechnology ETF - \$7,100
- MSCI ACWI Index (Net) (USD) - \$18,286
- Solactive Genomics Index (NR) (USD) - \$7,314



Average Annual Total Returns as of November 30, 2024

Fund/Index Name	Annualized Since Inception		
	1 Year	5 Years	
Global X Genomics & Biotechnology ETF	4.03%	-7.02%	-5.87%
MSCI ACWI Index (Net) (USD)	26.12%	11.36%	11.25%
Solactive Genomics Index (NR) (USD)	4.76%	-6.55%	-5.38%

Since its inception on April 5, 2019. The line graph represents historical performance of a hypothetical investment of \$10,000 in the Fund since inception. Returns shown are total returns, which assume the reinvestment of dividends and capital gains. The table and graph presented above do not reflect the deduction of taxes a shareholder would pay on Fund distributions or the redemption of Fund shares. **Past performance is not indicative of future performance.** Call 1-888-493-8631 or visit <https://www.globalxetfs.com/funds/gnom/> for current month-end performance.

Key Fund Statistics as of November 30, 2024

Total Net Assets

\$79,156,476

Number of Portfolio Holdings

46

Total Advisory Fees Paid


\$451,671

Portfolio Turnover Rate

18.89%

What did the Fund invest in?

Asset/Country Weightings*



* Percentages are calculated based on total net assets.

Top Ten Holdings

<u>Holding Name</u>	<u>Percentage of Total Net Assets</u>
Natera	5.6%
Veracyte	5.2%
Arrowhead Pharmaceuticals	5.1%
CRISPR Therapeutics	4.4%
Bio-Techne	4.3%
BioNTech ADR	4.2%
Agilent Technologies	4.1%
QIAGEN	4.1%
Sarepta Therapeutics	4.0%
Illumina	4.0%

Material Fund Changes

There were no material changes during the reporting period that are required to be disclosed in this report. For more complete information about other changes to the Fund, you may review the Fund's current prospectus, which is available upon request.

Additional Information

For additional information about the Fund, including its prospectus, financial information, holdings, and proxy voting information, call or visit:

- 1-888-493-8631
- <https://www.globalxetfs.com/funds/gnom/>